Opposing Regulation of PROX1 by Interleukin-3 Receptor and NOTCH Directs Differential Host Cell Fate Reprogramming by Kaposi Sarcoma Herpes Virus by Yoo, Jaehyuk et al.
Opposing Regulation of PROX1 by Interleukin-3 Receptor
and NOTCH Directs Differential Host Cell Fate
Reprogramming by Kaposi Sarcoma Herpes Virus
Jaehyuk Yoo
1., Ha Neul Lee
1., Inho Choi
1, Dongwon Choi
1, Hee Kyoung Chung
1, Kyu Eui Kim
1,
Sunju Lee
1, Berenice Aguilar
1, Jinjoo Kang
1, Eunkyung Park
1, Yong Suk Lee
1, Yong-Sun Maeng
1, Nam
Yoon Kim
1, Chester J. Koh
2, Young-Kwon Hong
1*
1Department of Surgery, Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern
California, Los Angeles, California, United States of America, 2Division of Pediatric Urology, Children’s Hospital Los Angeles and University of Southern California Keck
School of Medicine, Los Angeles, California, United States of America
Abstract
Lymphatic endothelial cells (LECs) are differentiated from blood vascular endothelial cells (BECs) during embryogenesis and
this physiological cell fate specification is controlled by PROX1, the master regulator for lymphatic development. When
Kaposi sarcoma herpes virus (KSHV) infects host cells, it activates the otherwise silenced embryonic endothelial
differentiation program and reprograms their cell fates. Interestingly, previous studies demonstrated that KSHV drives BECs
to acquire a partial lymphatic phenotype by upregulating PROX1 (forward reprogramming), but stimulates LECs to regain
some BEC-signature genes by downregulating PROX1 (reverse reprogramming). Despite the significance of this KSHV-
induced bidirectional cell fate reprogramming in KS pathogenesis, its underlying molecular mechanism remains undefined.
Here, we report that IL3 receptor alpha (IL3Ra) and NOTCH play integral roles in the host cell type-specific regulation of
PROX1 by KSHV. In BECs, KSHV upregulates IL3Ra and phosphorylates STAT5, which binds and activates the PROX1
promoter. In LECs, however, PROX1 was rather downregulated by KSHV-induced NOTCH signal via HEY1, which binds and
represses the PROX1 promoter. Moreover, PROX1 was found to be required to maintain HEY1 expression in LECs,
establishing a reciprocal regulation between PROX1 and HEY1. Upon co-activation of IL3Ra and NOTCH, PROX1 was
upregulated in BECs, but downregulated in LECs. Together, our study provides the molecular mechanism underlying the cell
type-specific endothelial fate reprogramming by KSHV.
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Introduction
Kaposi sarcoma (KS) was originally described by a Hungarian
doctor Morris Kaposi in 1872, but did not attract much scientific,
clinical and public attention until 1980s when acquired immuno-
deficiency syndrome (AIDS) became an epidemic and KS was
subsequently found to be the most common cancer among HIV-
positive individuals [1]. KS-associated herpes virus (KSHV), also
known as human herpes virus (HHV)-8, was identified in 1994 as
the causative agent for KS [2]. KSHV is a member of the gamma
herpes virus superfamily and, similar to other herpes virus, has
distinct latent and lytic stages. While KS tumor formation is
initiated by latent infection of host cells by KSHV, a small fraction
of latent cells spontaneously undertakes the lytic phase, a
reproductive replication process that releases the infectious viral
particles for another round of infection [1]. During the latent
infection, KSHV expresses only a handful of genes among its some
90 viral genes and these latent genes include latency-associated
nuclear antigen (LANA), viral cyclin-D homolog (vCyc-D), viral
FLICE-inhibitory protein (v-FLIP) and kaposin isoforms [3–8].
KS tumors are often associated with vessel-like spaces that are
filled with immune cells and red blood cells, and the proliferating
tumor cells of KS are now believed to be originated from KSHV-
infected vascular endothelial cells [9]. The endothelial origin of the
KS tumor cells was first proposed about 45 years ago based on the
expression of blood vascular endothelial cell (BEC) markers by KS
cells [10]. However, identification of new signature genes for
lymphatic endothelial cells (LECs) in the 1990s prompted a re-
evaluation on the histogenetic origin of the KS tumor cells. A
number of research groups have subsequently reported the
expression of LEC-markers in all stages of KS tumors, in addition
to the previously identified BEC-specific molecules [11]. More-
over, KSHV has been reported to be able to infect both BECs and
LECs under in vitro culture condition [12].
Importantly, we and other have reported that KSHV induces a
host cell fate reprogramming [13–15]. When KSHV infects BECs,
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On the contrary, when KSHV infects LECs, the host cells express
some of the BEC-associated genes. Importantly, neither of these
host cell fate reprogramming processes is a complete trans-
differentiation, but rather KSHV infection directs the host cells to
move away from their original cell identities and to end up
somewhere in between the two endothelial cell fates, exhibiting
mixed cell phenotypes, based on the genome-wide transcriptional
profiling studies [12–15]. Thus, considering the fact that BECs
differentiate to become LECs during embryogenesis [16], KSHV-
infected BECs are considered to undertake a ‘‘forward’’ differen-
tiation, and KSHV-infected LECs go through a ‘‘reverse’’
differentiation [12–15]. We and others have demonstrated that
KSHV induces this host cell type-specific reprogramming by
deregulating the expression of PROX1 [12–15], a homeodomain
transcriptional regulator that functions as the master control
protein in LEC-differentiation [16,17]. Whereas KSHV upregu-
lates PROX1 in BECs where PROX1 is not expressed, the virus
downregulates PROX1 in LECs, a cell type which abundantly
expresses PROX1 [12–15]. This host-specific bidirectional regu-
lation of PROX1 and host cell fate reprogramming by KSHV are
of great biological and pathological significance to better
understand the host-virus interaction. Nonetheless, the underlying
molecular mechanism remains undefined.
Several signal transduction pathways and transcriptional factors
have been identified to regulate the expression of PROX1 [18–
22]. Among them, interleukin (IL)-3 and NOTCH signals have
been previously implicated with KS pathogenesis [23–26]. The IL-
3 receptor (IL3R) consists of a heterodimer of an a-subunit and a
b-subunit: While IL3R a-subunit (IL3Ra/CD123) determines the
receptor specificity for IL3, IL3R b-subunit (IL3Rb/CD123),
having a long cytoplasmic domain, is responsible for transducing
external signals and can form heterodimers with IL5 receptor a-
subunit and granulocyte-macrophage colony stimulating factor
(GM-CSF) receptor a-subunit to make IL5R and GM-CSFR,
respectively [27]. IL-3, a potent stimulator of differentiation of
hematopoietic stem cells, was found to trans-differentiate cultured
BECs to LECs by upregulating PROX1 expression [18].
Moreover, IL-3 is constitutively expressed and secreted by
cultured LECs and required to maintain the LEC-phenotype in
vitro [18]. On the other hand, we have reported that NOTCH
signal suppresses the lymphatic phenotype by downregulating
lymphatic cell fate regulators, PROX1 and COUP-TFII, through
its effector Hey1 and Hey2 [22].
In this report, we defined the molecular mechanism underlying
the host-specific bidirectional regulation of PROX1 by KSHV.
We found that KSHV activates both IL3Ra and NOTCH
pathways and that these two pathways opposingly regulate
PROX1 expression in blood versus lymphatic-lineage endothelial
cells. Our data show that IL3Ra pathway serves as an activating
signal for PROX1 expression in KSHV-infected BECs and human
umbilical vein endothelial cells (HUVECs), whereas NOTCH acts
as a repression signal for PROX1 expression in KSHV-infected
LECs. In summary, KSHV-induced co-activation of these two
opposing signals results in PROX1-upregulation in KSHV-
infected BECs and HUVECs, but PROX1-downregulation in
KSHV-infected LECs. Together, our data provide the molecular
mechanism underlying the cell type-specific regulation of PROX1
by KSHV.
Results
KSHV differentially regulates PROX1 expression in blood
vs. lymphatic-lineage endothelial cells
We and others have previously reported that KSHV infection of
primary human BECs resulted in upregulation of otherwise
silenced PROX1 along with a lymphatic reprogramming of host
cell fate [13–15]. Interestingly, however, it was also reported that
KSHV infection of primary human LECs resulted in downreg-
ulation of PROX1 [12]. To investigate whether these seemingly
inconsistent results may be due to experimental variations among
different research groups, or due to endothelial lineage (BEC vs.
LEC)-specific differential regulation of PROX1 by KSHV, we
performed a series of comparative analyses of KSHV-mediated
PROX1 regulation by using the same donor-derived primary
neonatal human BECs and LECs, along with HUVECs from
different donors. In agreement with the previous reports [12–15],
quantitative real time RT-PCR (qRT-PCR) revealed that KSHV-
infection upregulated PROX1 in BECs and HUVECs, while
downregulating PROX1 in LECs (Fig. 1A). Western blot analyses
further confirmed that the steady-state level of PROX1 protein
was increased in BECs and HUVECs by KSHV infection, but
significantly decreased in LECs upon KSHV-infection. Thus, our
study confirmed that KSHV differentially regulates the expression
of PROX1 in blood versus lymphatic-lineage endothelial cells by
upregulating PROX1 in BECs and HUVECs where PROX1 is
not expressed, while downregulating in LECs where PROX1 is
abundantly expressed.
IL3Ra plays an important role in KSHV-mediated PROX1
upregulation in BECs
Previous studies have demonstrated that IL-3 activates PROX1
expression in BECs and HUVECs, but not in LECs, [18] and that
KSHV infection of microvascular endothelial cells strongly
induces expression and secretion of IL-3 [26]. These reports have
led us to investigate whether IL-3 signaling plays a role in
PROX1-upregulation by KSHV in BECs and HUVECs. Indeed,
KSHV-infection significantly upregulated the expression of IL3
receptor alpha (IL3Ra/CD123) mRNA and protein in BECs,
HUVECs and LECs (Fig. 1B). We also determined the expression
of related receptors such as IL3Rb, IL5Ra and GM-CSFRa.
While IL3Rb, the other subunit of IL3 receptor, was found to be
Author Summary
Kaposi’s sarcoma (KS) is one of the most common
neoplasms in HIV-positive individuals and organ transplant
recipients. KS-associated herpes virus (KSHV), also known
as human herpes virus (HHV)-8, has been identified as the
causative agent and infects endothelial cells to form KS.
Importantly, we and others have discovered that when
KSHV infects endothelial cells of blood vessels, it repro-
grams host cells to resemble endothelial cells in lymphatic
vessels. On the other hand, when KSHV infects endothelial
cells in lymphatic vessels, the virus directs the host cells to
partially obtain the phenotypes of blood vessel endothelial
cells. These host cell reprogramming represent abnormal
pathological processes, which are not as complete as the
physiological process occurring during embryonic devel-
opment. Currently, it is not clear how and why this cancer
causing virus modifies the fate of its host cells. In this
study, we aimed to dissect the molecular mechanism
underlying the virus-induced host cell fate reprogramming
and found two important cellular signaling pathways,
interleukin-3 and Notch, playing key roles in the patho-
logical events. Our current study provides a better
understanding of KS tumorigenesis with a potential
implication in a new KS therapy.
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CSFRa, which can dimerize with IL3Rb to form receptors for IL5
and GM-CSF, respectively, were not regulated by KSHV (Fig. 1C).
Moreover, immunohistochemical analyses of KS tumor sections
demonstrated prominent expression of IL3Ra in human dermal
KS tumor cells (Fig. 1D).
Because IL-3 activates PROX1 expression in BECs and
HUVECs, but not in LECs [18], we investigated whether
overexpression of its receptor, IL3Ra, could upregulate PROX1
in each cell type. We found that adenoviral expression of IL3Ra
resulted in a strong upregulation of PROX1 mRNA and protein in
BECs and HUVECs, but not in LECs (Fig. 2A), suggesting that
the PROX1-upregulating signal by IL3Ra is operative only in
PROX1-deficient BECs and HUVECs and does not affect the
already abundant expression of PROX1 in LECs. Furthermore,
ectopic expression of IL3Ra in BECs and HUVECs resulted in
upregulation of various LEC-signature genes such as podoplanin
(PDPN), VEGFR3, FGFR3, LYVE1, CDKN1C (p57
Kip2),
ITGA1 (integrin a1), PPL (periplakin) and SLC (secondary
lymphoid chemokine) in both BECs and HUVECs (Fig. 2B),
indicating that IL3Ra may play an important role in lymphatic
reprogramming of KSHV-infected BECs and HUVECs.
We next set out to determine whether IL3Ra is essential for
KSHV-mediated PROX1 upregulation in BECs and HUVECs,
and thus inhibited IL3Ra using siRNAs or an IL3Ra-neutralizing
antibody. Indeed, both approaches showed that PROX1 inhibi-
tion could efficiently abrogate the KSHV-induced upregulation of
PROX1 mRNA and protein (Fig. 2C). These data demonstrate
that IL3Ra plays an integral role in PROX1 upregulation by
KSHV in BECs and HUVECs, but not in LECs.
STAT5 mediates the IL3Ra-induced PROX1 upregulation
by directly binding to the PROX1 promoter
The key downstream mediators for the IL3/IL3Ra pathway
include Jak2 and STAT5a/b, and activated STAT5a/b proteins
rapidly enter the nuclei and bind to the promoters of target genes
to modulate their gene expressions [28]. We thus investigated
whether STAT5a/b proteins are involved in the IL3Ra-mediated
PROX1 upregulation. Adenoviral overexpression of IL3Ra in
BECs, HUVECs and LECs revealed an increased phosphorylation
in STAT5a/b in BECs and HUVECs, but at much lesser degree
in LECs (Fig. 3A). We then overexpressed the wild type,
constitutive active or dominant negative form of STAT5b protein
in BECs, HUVECs and LECs by transient transfection and
Figure 1. Regulation of the expression of PROX1 and IL3Ra by KSHV in blood vs. lymphatic-lineage endothelial cells. (A) KSHV
upregulated PROX1 in BECs and HUVECs, but downregulated PROX1 in LECs based on quantitative real-time RT-PCR (qRT-PCR) and western blot
analyses. Latency-associated nuclear antigen (LANA) was used to confirm KSHV-infection and b-actin for equal loading in western analyses. (B) IL3Ra
was comparably upregulated by KSHV in the three cell types determined by qRT-PCR and western blot analyses. (C) Expression of IL3Rb, IL5Ra and
GM-CSFRa in BECs by KSHV infection was determined by qRT-PCR. (D) Immunohistochemistry analysis showed prominent expression of IL3Ra in KS
tumor cells (arrow-marked) in the skin of a HIV-positive patient. CTR, a control skin section from a normal neonatal foreskin; KS, Kaposi sarcoma tumor
section from a HIV-positive individual.
doi:10.1371/journal.ppat.1002770.g001
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PLoS Pathogens | www.plospathogens.org 3 June 2012 | Volume 8 | Issue 6 | e1002770Figure 2. IL3Ra plays a key role in KSHV-mediated PROX1 upregulation. (A) Adenoviral expression of IL3Ra increased the expression of
PROX1 mRNA and protein in BECs and HUVECs, but not in LECs based on qRT-PCR and western blot analyses. AdCTR, control adenovirus; AdIL3Ra,
IL3Ra-expressing adenovirus. (B) The expression of various LEC-associated genes such as PDPN, VEGFR3, FGFR3, LYVE1, CDKN1C, ITGA1, PPL and SLC
was determined by qRT-PCR in BECs or HUVECs transduced by a control (AdCTR) versus IL3Ra- (AdIL3Ra) adenovirus for 48 hours. The graph shows
Differential Host Cell Fate Reprogramming by KSHV
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ectopic expression of the constitutive active form of STAT5b
protein resulted in upregulation of PROX1 protein in BECs and
HUVECs, but did not change PROX1 expression in LECs
(Fig. 3B). Moreover, the IL3Ra-induced PROX1 upregulation
was significantly abrogated when the expression of STAT5a/b was
inhibited by siRNA-mediated knockdown (Fig. 3C), establishing a
key role of STAT5a/b in the IL3Ra-induced PROX1 upregula-
tion.
To further corroborate the molecular interaction between
STAT5a/b protein and the PROX1 gene, we next searched for
putative binding sites of STAT5a/b proteins in the PROX1
promoter regions of different animal species and mapped two or
three candidate sites in the PROX1 promoter regions of nine
mammals (human, chimp, mouse, rat, guinea pig, horse, rabbit,
dog and marmoset) (Supplemental Fig. S1). Importantly, both
DNA sequences and relative locations of the putative STAT5a/b
binding sites were found to be highly conserved among the nine
mammalian species. To further validate them as STAT5a/b
binding sites, we next performed chromatin immunoprecipitation
(ChIP) and gel electrophoretic mobility shift assays (EMSA) for the
human PROX1 promoter region. Indeed, our ChIP assay
detected a basal binding activity of endogenous STAT5 proteins
to the two putative STAT5a/b sites (termed E1 and E2) found
approximately 11.7- and 6.5-kb upstream, respectively, from the
human PROX1 initiation codon in BECs and HUVECs, and
these binding activities were significantly increased by IL3Ra
overexpression (Fig. 3D). Moreover, EMSA demonstrated that
nuclear extracts isolated from IL3Ra-overexpressed BECs effi-
ciently caused a shift in the mobility of both E1 and E2 probes
(Fig. 3E). Addition of an anti-STAT5a/b antibody in the EMSA
reactions significantly inhibited formation of the protein/probe
complexes (Fig. 3F), indicating that E1 and E2 probes made
DNA/protein complexes with STAT5a/b proteins. Taken
together, these data demonstrate that STAT5a/b proteins play a
significant role in the IL3Ra-induced PROX1 upregulation in
BECs and HUVECs by directly binding to the PROX1 promoter
region.
NOTCH directs the KSHV-mediated PROX1
downregulation in lymphatic endothelial cells
We next set out to investigate how KSHV-infection resulted in
downregulation of PROX1 in LECs, despite the fact that KSHV
upregulates PROX1 in BECs and HUVECs. Previous studies
have shown an increased activity of the NOTCH pathway in
KSHV-infected endothelial cells and KS-tumor cells in vivo
[23,25,29,30]. Moreover, we have recently reported that activated
NOTCH represses PROX1 expression through HEY1 in LECs
[22]. Accordingly, we came up with a hypothesis that KSHV-
induced NOTCH activation may be involved in PROX1
downregulation in KSHV-infected LECs. Supporting this hypoth-
esis, KSHV-infection of all three cell types, BECs, HUVECs and
LECs, resulted in upregulation of HEY1 (Fig. 4A). Adenoviral
overexpression of NOTCH intracellular domain (NICD) caused a
significant downregulation of PROX1 in LECs, but not in BECs
and HUVECs (Fig. 4B&C). In addition, Notch activation in LECs
resulted in downregulation of additional lymphatic-signature genes
such as podoplanin (PDPN) and CDKN1C, suggesting a
suppressive role of Notch signaling in LEC phenotypes (Supple-
mental Fig. S2). Moreover, microarray-based analyses on the
NICD-induced modulation of the transcriptional profiles in
primary LECs (National Center for Biotechnology Information,
Gene Expression Omnibus accession number: GSE20978) support
the effect of Notch on LEC phenotype. Furthermore, we found
that HEY1, like NICD, was able to strongly repress the expression
of PROX1 protein, when overexpressed in LECs (Fig. 4D). Since
HEY1 is known to repress target gene expression by binding to the
promoter [31], we performed HEY1-ChIP assays against the
PROX1 promoter in primary LECs and found that HEY1 was
indeed physically associated with the PROX1 promoter around
the two transcriptional start sites (Fig. 4E&F). We then generated a
set of PROX1-promoter reporter constructs and found that a 1.8-
kb proximal promoter region was sufficient to deliver the HEY1-
mediated repression (Fig. 4G). Finally, inhibition of HEY1
expression by siRNA abrogated the KSHV-mediated downregu-
lation of PROX1 mRNA and protein in LECs (Fig. 4H).
Together, these findings demonstrate that NOTCH activation is
responsible for the KSHV-mediated PROX1 downregulation in
LECs, but not in BECs and HUVECs, and that the NOTCH
effector HEY1 directly binds to the PROX1 promoter to
downregulate its gene expression.
PROX1 is required to maintain the expression of HEY1 in
LECs: Reciprocal regulation between PROX1 and HEY1
We have previously reported that PROX1 physically and
functionally interacts with the orphan nuclear receptor COUP-TFII
to specify the cell fate of LECs [32]. We also performed a genome-
wide search for PROX1 target genes using microarray analyses and
identified a list of genes, whose expression was altered by PROX1
knockdown in LECs [32]. Interestingly, the microarray analyses
revealed that the expression of HEY1 was significantly downregu-
lated in LECs by PROX1 knockdown (GEO accession: GSE12846).
This unexpected regulation of HEY1 by PROX1 was further
confirmed using qRT-PCR of total RNAs isolated from LECs that
were transfected with siRNA against PROX1 and/or COUP-TFII
(Fig. 5A). Notably, knockdown of COUP-TFII, a PROX1-interact-
ing protein, did not alter the HEY1 expression. On the contrary,
adenoviral overexpression of PROX1, but not COUP-TFII, in LECs
resulted in a strong upregulation of HEY1 (Fig. 5B). We then asked
whether PROX1 could activate the proximal promoter of HEY1 and
thus performed a series of luciferase reporter assays using promoter
constructs of HEY1 and two other HEY familymembers,HEY2 and
HEYL. Indeed, the HEY1 promoter was found to be activated by
PROX1 wild type, but not by a PROX1 mutant lacking DNA-
binding activity [33] (Fig. 5C). Moreover, adenoviral expression of
PROX1 in human umbilical aortic endothelial cells (HUAEC) also
resulted in upregulation of HEY1 (Fig. 5D). We then performed
PROX1 ChIP assays against the HEY1 promoter and found that
PROX1 protein is physically associated with the HEY1 promoter
(Fig. 5E). Subsequently, a set of HEY1 promoter reporter constructs
was generated and used to further study the PROX1 regulation of
HEY1. Notably, a ,0.7 kb-long HEY1 promoter (pHey1C) was
sufficient to deliver the PROX1-mediated activation of the HEY1
promoter (Fig. 5F). Therefore, we concluded that PROX1 positively
regulates the expression of HEY1 by directly binding to its promoter.
Together with the findings above (Fig. 4), these data established a
reciprocal regulation between PROX1 and HEY1: HEY1 functions
as a repressor of PROX1 and PROX1 is required to upregulate or
fold changes in expression of each gene by IL3Ra-expressing adenovirus over the control virus. (C) Inhibition of IL3Ra by siRNA or a neutralizing
antibody partially abrogated the KSHV-mediated PROX1 upregulation in BECs and HUVECs, as determined by qRT-PCR (BECs and HUVECs) and
western blot (BEC only) analyses. siCTR, siRNA for the firefly luciferase; siIL3Ra, siRNA for IL3Ra; anti-IL3Ra, neutralizing antibody against IL3Ra.
doi:10.1371/journal.ppat.1002770.g002
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regulation, PROX1 could negatively regulate its own gene expres-
sion. To confirm this auto-regulation, we ectopically overexpressed
PROX1 in LECs using adenovirus that harbors the PROX1 open
reading frame (ORF) only and then determined the expression level
of the endogenous PROX1 by two qRT-PCR probes detecting the
PROX1 39-untranslated region (UTR), which is not present in the
adenovirus. Indeed, ectopic expression of PROX1 resulted in a
significant downregulation of the endogenous PROX1 (Fig. 5G).
Taken together, our data uncovered an intricate auto-regulatory
mechanism for the PROX1 gene expression that utilizes the HEY1
repressor, a component of NOTCH signal pathway.
Figure 3. STAT5a/b proteins bind to the PROX1 proximal promoter and mediate IL3Ra-induced PROX1 upregulation. (A) Adenoviral
overexpression of IL3Ra increased phosphorylation of STAT5a/b (p-STAT5a/b) in BECs and HUVECs, but not LECs. AdCTR, control adenovirus; AdIL3Ra,
IL3Ra-expressing adenovirus. The relative intensity ratio of the p-STAT5a/b band over the total STAT5a/b band is shown below the p-STAT5a/b
western blot result. (B) The constitutively active (CA), but not wild type (WT) or dominant negative (DN), form of STAT5b induced PROX1 upregulation
in BECs and HUVECs, but not in LECs. Comparable expression of FLAG-tagged rat STAT5b proteins (Flag) was confirmed by western blot assays. CTR, a
control vector. (C) Inhibition of STAT5a/b with siRNA-mediated knockdown abrogated the IL3Ra-induced PROX1 upregulation in BECs and HUVECs.
siCTR, siRNA for luciferase gene; siSTAT5a/b, siRNA for STAT5a/b. (D) STAT5a/b ChIP assay against the PROX1 promoter sequences revealed an
increased binding of STAT5a/b proteins to the two newly identified putative STAT5 binding sites (E1 and E2) upon adenoviral IL3Ra-overexpression in
BECs and HUVECs. Relative locations of E1, two PROX1 transcriptional start sites (TS1 based on the PROX1 Ensemble exon number ENSE00001936642
and TS2 based on ENSE00001443122), E2 and the PROX1 initiation codon (ATG) are illustrated. (E) EMSA showing that nuclear fractions isolated from
BECs contain binding activity for the E1 and E2 sites and that this binding activity was increased upon IL3Ra-overexpression. (F) The binding activity
to the E1 and E2 sites could be inhibited by an anti-STAT5a/b antibody, indicating that the binding activity was caused by STAT5a/b proteins. Arrow-
pointed bands in E and F indicate STAT5a/b protein complex with the isotope-labeled E1 and E2 DNA probes. Asterisks point a protein/probe
complex that did not respond to the anti-STAT5a/b antibody and thus was likely caused by an unrelated factor.
doi:10.1371/journal.ppat.1002770.g003
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regulatory forces in blood versus lymphatic-lineage
endothelial cells
Since our studies above showed that KSHV activates both
IL3Ra and NOTCH pathways simultaneously, we next asked how
these two signals counteract with each other in regulating the
expression of PROX1 in BECs versus LECs. To address this
question, we concurrently activated both pathways by adenoviral
expression of IL3Ra and NICD in BECs, HUVECs and LECs.
Notably, co-expression of IL3Ra and NICD resulted in differential
regulation of the PROX1 expression in blood vs. lymphatic-
lineage endothelial cells (Fig. 6A,B). In BECs and HUVECs,
PROX1 was found to be upregulated by co-expression of IL3Ra
and NICD. In LECs, however, PROX1 was rather downregulated
Figure 4. NOTCH pathway plays a major role in KSHV-mediated PROX1 downregulation in LECs. (A) HEY1, an effector of NOTCH, was
strongly upregulated by KSHV in BECs, HUVECs and LECs, as determined by qRT-PCR. (B,C) While activated NOTCH repressed PROX1 expression in
LECs, the PROX1 expression level remained unchanged in BECs or HUVECs by NOTCH, based on qRT-PCR (B) and western blot (C) analyses. AdCTR,
control adenovirus; AdNICD, NICD-expressing adenovirus. (D) Expression of PROX1 protein was strongly repressed by adenoviral overexpression of
NICD and HEY1 in LECs based on western blot analyses. AdHey1: FLAG-HEY1-expressing adenovirus. (E) HEY1 ChIP assay against the human PROX1
promoter shows that HEY1 protein is associated with the PROX1 promoter. Primary LECs transduced with AdHey1 (expressing FLAG-tagged HEY1)
were used to perform ChIP assays using an anti-FLAG antibody and two sets of primers against the human PROX1 promoter. Relative location of the
primer sets is marked in panel F. (F) A diagram illustrating the relative location of the start codon (ATG), two PROX1 transcription start sites (TS1, TS2),
the HEY1 ChIP primer sets and the boundaries of the PROX1 promoter fragments that were used to generate the luciferase reporter constructs. (G)
Luciferase-reporter assays using PROX1-promoter constructs revealed that PROX1 repression by HEY1 can be mediated through a 1.8-kb promoter
fragment (PROX1_P3). (H) Inhibition of HEY1 by siRNA abrogated the KSHV-mediated downregulation of PROX1 based on qRT-PCR and western blot
analyses.
doi:10.1371/journal.ppat.1002770.g004
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PLoS Pathogens | www.plospathogens.org 7 June 2012 | Volume 8 | Issue 6 | e1002770by activation of the two pathways. These data indicate that the
IL3Ra-induced PROX1 activating signal is more effective than
the NICD-mediated PROX1 repression in BECs and HUVEC,
resulting in PROX1 upregulation. On the contrary, the NICD-
mediated repression is more prominent than the IL3Ra-induced
activation in LECs, causing downregulation of PROX1. Taken
together, co-activation of the IL3Ra and NOTCH pathways
yields a differential expression of PROX1 and may account for the
KSHV-mediated endothelial lineage-specific differential regula-
tion of PROX1 and accompanying host cell fate reprogramming.
Discussion
Despite their morphological and functional similarities, endo-
thelial cells exhibit remarkable heterogeneity and plasticity.
Heterogeneity of endothelial cells is profoundly contributed by
their plastic cell fates in response to internal and external stimuli
such as immunological, functional, metabolic, anatomical and
hemodynamic signals [34,35]. In addition to these physiological
stimuli, pathological insults can also incite the plasticity of
endothelial cell identities. We and others have previously reported
that KSHV-infection reprograms the host cell identity by
Figure 5. PROX1 upregulates HEY1 in primary LECs. (A) Knockdown of PROX1, but not COUP-TFII, resulted in downregulation of HEY1 in LECs.
qRT-PCR analyses were performed to determine the expression of HEY1, PROX1 and COUP-TFII in primary LECs that were transfected for 48 hours
with siRNAs targeting the firefly luciferase (siCTR), PROX1 (siProx1), COUP-TFII (siCOUP) or both PROX1 and COUP-TFII (siBOTH). (B) Adenoviral
expression of PROX1, but not of COUP-TFII, increased the expression of HEY1 mRNA in LECs. qRT-PCR analyses were performed to determine the level
of HEY1 mRNA in LECs that were transduced with a control (AdCTR), PROX1 (AdProx1), COUP-TFII (AdCOUP) adenovirus or with both PROX1 and
COUP-TFII (AdBOTH) for 48 hours. (C) Luciferase reporter constructs of the promoters of HEY1, Hey2 or HeyL were transiently transfected into HEK293
cells along with a control vector (Empty Vector), PROX1 wild type (Prox1_WT) or PROX1 DNA-binding mutant (Prox1_Mut). After 48 hours, luciferase
activity was measured and each value was normalized by total cell lysate amounts. (D) PROX1 also upregulated HEY1 in aortic endothelial cells
(human umbilical aortic endothelial cells, HUAEC). Relative expression was determined for HEY1, Hey2 and PROX1 in primary HUAECs that were
transduced with a control or PROX1-adenovirus for 48 hours. (E) Chromatin immunoprecipitation (ChIP) assay demonstrating a physical association
between PROX1 protein and the HEY1 promoter in LECs. Primary LECs were transfected with a control (LEC/CTR) or a PROX1-expressing vector (LEC/
Prox1) for 48 hours and then subjected to ChIP analyses using a normal IgG (IgG) or anti-PROX1 (a-Prox1) antibodies. (F) A ,0.6-kb HEY1 proximal
promoter was sufficient to deliver the PROX1-mediated repression of HEY1 expression. Reporter constructs of the HEY1 promoter were transfected
with a control or PROX1-expressing vector into HEK293 cells for 48 hours. (G) Ectopic expression of PROX1 in LECs resulted in downregulation of
endogenous PROX1. LECs were transduced with a control (AdCTR) or PROX1 (AdProx1) adenovirus. After 48 hours, qRT-PCR was performed by using
two sets of probes that target the 39 untranslated region (UTR) of endogenous PROX1. All data were shown as a relative average expression 6
standard deviation (SD).
doi:10.1371/journal.ppat.1002770.g005
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whose expression is deregulated by KSHV, plays a key role in this
pathological host cell fate reprogramming [12–15]. Although this
concept of the pathogen-induced host cell fate reprogramming has
forwarded a new view on the histogenetic origin of KS tumor cells
[12–15], two subsequent questions, how and why, remained to be
answered. In this study, we aimed to address the first question,
how, by studying the KSHV-mediated regulation of PROX1 in
context of the virus-induced host cell fate plasticity.
By using primary BECs and LECs from the same donors, we
confirmed that KSHV-infection induces endothelial cell type-
specific differential regulation PROX1, as previously reported
[13–15]. Because only unidirectional differentiation (BECs to
LECs) occurs during physiological (embryonic) endothelial cell
differentiation, it is important to understand how KSHV
pathologically activates a differentiation program by upregulating
PROX1 in one cell type and a de-differentiation by downregu-
lating PROX1 in another cell type [12]. Based on the data
presented above, we propose a novel hypothesis for the molecular
mechanism underlying the KSHV-mediated host cell type-specific
regulation of PROX1 (Fig. 7A). We hypothesize that KSHV-
infection results in simultaneous activation of the IL3Ra and
NOTCH pathways and delivers both positive and negative
regulatory signals, respectively, to the PROX1 gene in both blood
and lymphatic-lineage endothelial cells. Under this condition, we
believe that it is the initial expression status of PROX1 that brings
up the differential consequences: An activating signal (IL3Ra) will
cause a discrete change than a repressive signal (NOTCH) in the
PROX1-deficient BECs and HUVECs, whereas a repressive
signal (NOTCH) will have a higher impact than an activating
signal (IL3Ra) in the PROX1-expressing LECs. Moreover,
because LECs constitutively secret IL-3 to maintain their
phenotypes [18], IL3Ra-mediated signaling is already active in
LECs and thus the increased expression of IL3Ra by KSHV does
not provide an additional upregulation of PROX1. Accordingly,
KSHV-mediated upregulation of PROX1 directs a ‘‘forward’’
reprogramming (differentiation) of BECs and HUVECs to acquire
the lymphatic phenotype, but KSHV-mediated downregulation of
PROX1 enables a ‘‘reverse’’ reprogramming (dedifferentiation) of
LECs. Importantly, since both pathological cell fate reprogram-
ming are incomplete processes, KSHV-infection forces host
endothelial cells to move away from their original cell fates and
to end up somewhere in between the two endothelial cell fates, as
described by previous studies [12–15].
Another key finding in the current study is the reciprocal
regulation between PROX1 and HEY1 (Fig. 7B). We found that
HEY1, the only transcriptional repressor of PROX1 identified to
date [22], directly binds to the PROX1 proximal promoter to
repress its transcription. Moreover, our current study revealed that
PROX1 is required to maintain the expression of HEY1 in LECs.
This PROX1/HEY1 reciprocal regulation put forward three
important implications. First, a positive regulatory signal of
PROX1 expression will be always counteracted by the parallel
upregulation of its own repressor HEY1 and thus PROX1
expression will be maintained under a certain threshold level that
is set by HEY1. This speculation is consistent with the finding that
the activating signal by IL3Ra did not additionally increase
PROX1 expression in LECs where PROX1 is already abundantly
expressed (Fig. 2A). Second, since HEY1 has been known to
repress the expression of the viral lytic phase initiator gene RTA
and thus to play an important role in the latency control [36,37],
PROX1 may indirectly contribute to host regulation of the viral
latency phase by maintaining the HEY1 expression. Third, HEY1
requires PROX1 for its own expression and thus will be unable to
entirely shut down PROX1 expression, even if NOTCH signal is
activated. This regulation will serve as a feedback control to
counteract the NOTCH-induced repression of PROX1, which is
mediated by HEY1. Therefore, the reciprocal regulation between
PROX1 and HEY1 adds another layer of complexity to the
opposing regulatory circuits of PROX1 expression by IL3Ra and
NOTCH upon KSHV-infection.
Moreover, since KS cells secrete a number of chemokines and
cytokines and also recruit various immune cells, multiple signal
transduction pathways have been associated with KS tumorigen-
esis [8,9]. Considering the numerous chemokines and cytokines
that KS cells are constantly exposed to [26,38,39], it is likely that
PROX1 expression would be controlled by multiple activating and
repressing signals. In fact, activation of Jak2/Stat3 by gp130 has
been demonstrated to be important in KSHV-mediated upregula-
tion of PROX1 and lymphatic reprogramming [40]. Gp130/Stat3
and IL3Ra/STAT5 may cooperate to regulate the PROX1
expression in KSHV-infected cells, especially when the two
Figure 6. IL3Ra and NOTCH pathways opposingly regulate PROX1 and bring up different outcomes in BECs/HUVECs versus LECs.
(A) Over-expression of NICD in BECs and HUVECs did not significantly alter PROX1 expression in BECs and HUVECs, but downregulated PROX1 in LECs.
In comparison, expression of IL3Ra induced PROX1 expression in BECs and HUVECs, but did not further upregulate PROX1 in LECs. (B) Simultaneous
expression of NICD and IL3Ra resulted in PROX1 upregulation in BECs and HUVECs, but PROX1 downregulation in LECs. NICD is tagged with the V5
antigen.
doi:10.1371/journal.ppat.1002770.g006
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this notion, inhibition of IL3Ra in KSHV-infected BECs and
HUVECs only partially abrogated PROX1 upregulation by
KSHV (Fig. 2C).
One important question brought up by the current study is to
determine which KSHV viral proteins are responsible for the
upregulation of IL3Ra and NOTCH. We speculate that the latent
protein kaposin-B may be involved in upregulation of IL3Ra
because kaposin-B has been reported to upregulate expression of
various cytokines such as granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) via stabilizing their mRNAs [42] and,
notably, GM-CSF has been demonstrated to be a key activator of
IL3Ra expression in different cell types [43–46]. Therefore, it will
be very interesting to investigate if kaposin-B regulates IL3Ra
expression. On the other hand, the molecular mechanism
underlying the KSHV-mediated NOTCH upregulation has been
recently documented by two studies [25,47], which identified the
KSHV-encoded vFLIP, LANA and vGPCR to be responsible for
the upregulation of various NOTCH signal components, including
the receptors (NOTCH1,4), ligands (Dll1/4, Jag1) and down-
stream effectors (Hey1) of the NOTCH signaling pathway.
Although our current study addresses the how part to a certain
extent, numerous questions on why remain unanswered: Why does
KSHV induces its host cell fate reprogramming? It will be intriguing to
determine whether this host cell fate reprogramming is a mere by-
product of the viral infection of endothelium, a cell type that
happens to be highly plastic in their cell identity, or whether the
compromised cell identity provides any pathological advantage to
KS tumorigenesis. Further studies should be warranted on these
important questions.
Materials and Methods
Cell cultures and gene expression reagents
Human primary dermal blood vascular endothelial cells (BECs)
and lymphatic endothelial cells (LECs) were isolated from de-
identified neonatal human foreskins and cultured as previously
described [32] with an approval of the University of Southern
California Internal Review Board (PI: YK Hong). Primary human
umbilical venous endothelial cells (HUVECs) and human umbil-
ical aortic endothelial cells (HUAEC) were purchased from Lonza
(Basel, Switzerland) and cultured in EGM-2 medium (Lonza).
Primary endothelial cells were transfected with siRNA by
electroporation as previously described [48]. Sequence informa-
tion of siRNAs are as follows: human HEY1 [22], PROX1 [22],
STAT5a/b (SC29495, Santa Cruz Biotechnology), COUP-TFII
(UCGUACCUGUCCGGAUAUA, UAUAUCCGGACAGGU-
ACGA), control (fire fly luciferase, CUUACGCUGAGUACU-
UCGAdTdT), and IL3Ra (CUGGGACCUUAACAGAAA-
UdTdT). Adenovirus for PROX1 [49], COUP-TFII [32] and
NICD [50] were previously described. Adenovirus expressing V5-
tagged NICD was a kind gift from Dr. Lucy Liaw (Maine Medical
Center Research Institute) [51]. Adenovirus for human IL3Ra was
constructed by transferring the IL3Ra coding sequences from
AxCALNLhIL-3Ra (Riken BRC DAN Bank, Japan) into Ad-
Track-CMV shuttle vector and then recombined with AdEasy-1
based on the reported protocol of adenovirus construction [52].
Expression vectors for Flag-tagged rat-STAT5b (wild type,
constitutive active, dominant negative) [53] were kind gifts from
Dr. Peter Rotwein (Oregon Health and Science University).
KS specimen, KSHV production and infection
KS specimens were provided from the AIDS and Cancer
Specimen Resource (ACSR) with an approval of the University of
Southern California Internal Review Board (PI: YK Hong).
Infectious KSHV was purified from BCBL-1 cells as we previously
described [54]. Endothelial cells were infected with KSHV for 2,4
days and infectivity was measured by westernblot analyses for KSHV
LANA. For inhibition of IL3Ra, BECs or HUVECs were transfected
with IL3Ra siRNA or treated with anti-IL3Ra antibody (1 mg/ml)
24 hours before KSHV-infection and 48 hours post infection, RNA
Figure 7. Working hypotheses for the KSHV-mediated bidirectional host cell fate reprogramming and for the opposing regulation
of PROX1 by IL3Ra and NOTCH. PROX1 expression level of host cells is the key determinant for the differential PROX1 regulation by KSHV. In
PROX1-absent BECs and HUVECs, the PROX1-inducing IL3Ra pathway overwhelms the PROX1-repressive NOTCH pathway, resulting in PROX1
upregulation and acquisition of LEC-phenotype (Forward Reprograming). In PROX1-abundant LECs, the PROX1-repressive NOTCH pathway is more
productive than the PROX1-inducing IL3Ra pathway, resulting in PROX1 downregulation and regaining BEC-phenotype (Reverse Reprograming).
Importantly, however, these reprogramming processes appear to be incomplete differentiation events and thus KSHV-infected endothelial cells
exhibit both (mixed) BEC and LEC-phenotypes.
doi:10.1371/journal.ppat.1002770.g007
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STAT5a/b expression by siRNA was similarly performed.
Quantitative real time RT-PCR, immunostaining and
immunoblot analyses
Real-time RT-PCR was performed by using TaqMan EZ RT-
PCR Core Reagent (Applied Biosystems). Each reaction was
multiplexed for target gene and b-actin for normalization.
Sequences of two Taqman primer/probes for the 39 UTR are
(TGGTTTTCCCTTTTACAATCGAA/GAATTTGGAGAGA-
CAGGCTTTTG/FAM-TTGTGCCTCCCAAGTGCATTGG-
AA-TAMRA; TGGTTTTCCCTTTTACAATCGAA/GAATT-
TGGAGAGACAGGCTTTTG/FAM-TTGTGCCTCCCAAG-
TGCATTGGAA-TAMRA). Sequences for other primers and
probes used for this study will be provided upon request.
Immunostaining was performed on formalin-fixed paraffin
embedded KS tissue specimens by following a standard immuno-
staining protocol [32]. Sources of antibodies for immunostaining
or western blot analyses are PROX1 (Millipore Corporation, MA),
b-actin and Flag (Sigma-Aldrich Corporation), STAT5 and
phospho-STAT5 (Cell Signaling Technology), IL3Ra (clone
7G3, BD Bioscience), V5 (Invitrogen) and LANA (Advanced
Biotechnologies Inc, Maryland).
ChIP and EMSA
ChIP assays were performed as previously described [22].
BECs, HUVECs or LECs transduced with a control or IL3Ra-
expressing adenovirus for 48 hours were subjected to ChIP assays
by using anti-STAT5a/b antibody. Genomic/protein precipitants
were PCR-amplified by using primers against the E1 site
(CTTCCCTTCTTCAGGGTGCT/TCACGCCTCCTGTTC-
TTTCT) or the E2 site (TAGCTCAAGGAGGCAGGTTG/
GGGCATGAGTGGAAAAGAGA) sites (Fig. 4A). Sequences of
the primers used for HEY1 ChIP assays against human PROX1
are as follows (Primer Set 1: GAGAGGCTCGGTCCCACT/
TGAGTAATGGGAGGCTCTTTTC; Primer Set 2: GAGCC-
TCCCATTACTCAGACC/GAGGCTCCCGCTTAGAAACT).
EMSA was performed as previously described [22,54]. Briefly,
nuclear lysates isolated from BECs or LECs transduced with a
control or IL3Ra-expressing adenovirus were incubated with
32P-
labeld oligonucleotide probes containing the putative E1 site for
STAT5a/b (ATCTGGTTGTAATTCTCAGAATTGGTT/TC-
CTAAACAAACCAATTCTGAGAATTA) or the E2 site (GCT-
TGTTTTTATTTTTCCGAGAAGATC/GACAGCACAGAT-
CTTCTCGGAAAAATA) in the binding buffer and subjected to
polyacrylamide gel electrophoresis. For EMSA blocking assays, the
nuclear extracts were added to the binding reactions in the
presence of a STAT5a/b antibody (1 mg/ml).
Luciferase assay
The reporter constructs of PROX1 promoter were constructed
as follows. A 5.1-kb human PROX1 promoter was PCR-amplified
from human genomic DNA using primers (GTCCAGGGCGTG-
TACTGAG/CGGCTGCAATGGTGTATTATT) and cloned
into EcoRV site of pBluescriptIISK(-) in a reverse orientation. A
NheI/XhoI fragment was then transferred to NheI/XhoI sites of
pGL3 (Promega) to generate the PROX1_P1 vector. Subsequent-
ly, a 1.6-kb PstI or a 3.3-kb MluI fragment was deleted from
PROX1_P1 and self-ligated after Klenow treatment to construct
PROX1_P2 and PROX1_P3, respectively. Luciferase reporter
constructs [55] for mouse HEY1, HEY2 and HEYL were
generously provided by Dr. Eric Olson (University of Texas
Southwestern Medical Center, Dallas). The reporter constructs of
the mouse Hey1 promoter were constructed by modifying a 2.9-kb
mouse Hey1 construct [56] (renamed here as pHey1A) generously
provided by Dr. Manfred Gessler (Theodor-Boveri-Institut fuer
Biowissenschaften, Germany). Deletion constructs were generated
by self-ligation after digesting pHey1A with EcoRV/MscI
(pHey1B), EcoRV/ApaI (pHey1C), EcoRV/AscI (pHey1D),
EcoRV/SacII (pHey1E) or EcoRV/NcoI (pHey1F). Luciferase assays
were performed as follows. HEK293T was transiently transfected
in 12-well plates in DMEM, 10% FCS. Cells were transfected
with a total of 1 ug of DNA by Lipofectamin 2000 (Invitrogen).
After 48 hours, cells were washed and lysed in 200 mL of PBS by
three-time-repetition of freeze-thaw cycles. Cells were harvested
and cell debris was removed by centrifugation. Protein concen-
trations were measured by Bradford assay and luciferase activity
was measured using the Bright-Glo buffer (Promega) by
Mikrowin2000 program, Luminometer (Plate CHAMELE,
HIDEX). Each experiment was repeated 3 times with each
reaction measured in triplicates.
Supporting Information
Figure S1 Identification of the putative Stat5 binding
sites in the PROX1 promoter regions in nine mammals.
A multiple genome alignment tool, MAUVE [57], was used to align
the PROX1 upstream sequences (,12-kb upstream from the
translation initiation codon) from human, chimp, mouse, rat, guinea
pig, horse, rabbit, dog and marmoset. PROX1 translation initiation
sites (Prox1 ATG codon) and relative locations (box) of the putative
Stat5 binding sites of each species are marked in the genomic maps.
Cross-species sequence conservations are estimated by red peaks and
the asterisks mark the genomic areas where DNA sequence is
unavailable. Genome assemblies used for this DNA sequence
alignment are as follows: Human (Feb. 2009, GRCh37/hg19),
Chimp (Mar. 2006, CGSC 2.1/panTro2), Mouse (July 2007,
NCBI37/mm9), Rat (Nov. 2004, Baylor 3.4/rn4), Guinea pig (Feb.
2008, Broad/cavPor3), Horse (Sep. 2007, Broad/equCab2), Rabbit
(Apr. 2009, Broad/oryCun2), Dog (May 2005, Broad/canFam2),
Marmoset (March 2009, WUGSC 3.2/calJac3). Actual DNA
sequences of the putative Stat5 binding sites are shown in the bottom
table.
(PDF)
Figure S2 Effect of Notch activation in human primary
LECs. Adenoviral expression of NICD in primary LECs resulted
in suppression of LEC-phenotypes, including downregulation of
PROX1, PDPN and CDK1NC.
(PDF)
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